Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study of TAR DNA-binding protein 43 (TDP43) for the treatment of amyotrophic lateral sclerosis (ALS) patients

Next Previous
X
Search
Trial Profile

A phase 1/2 study of TAR DNA-binding protein 43 (TDP43) for the treatment of amyotrophic lateral sclerosis (ALS) patients

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMDX-2011P (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Diagnostic use; First in man

    • Most Recent Events

    • 13 Dec 2021 New trial record
    • 06 Dec 2021 According to an Amydis media release, the company is planning to initiate this clinical trial by first half of 2022.
    • 06 Dec 2021 According to an Amydis media release, the company has completed the pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA). The FDA has agreed with the overall design of this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top